Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Susanne Jackson"'
Autor:
Deborah H. Allen, Amy Walker, Jeremy N. Rich, Sandra Tourt-Uhlig, Cindy Bohlin, Allan H. Friedman, John H. Sampson, Susanne Jackson, Mary Lou Affronti, Sridharan Gururangan, Karen Ziegler, James M. Provenzale, Jennifer A. Quinn, Michael A. Badruddoja, James E. Herndon, James J. Vredenburgh, Darrell D. Bigner, David A. Reardon, Steven Silverman, Henry S. Friedman, Jeannette M. Dowell
Publikováno v:
Neuro-Oncology. 6:134-144
In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG). We previously established the maximum tolerated dose of CPT-11 when admin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::660f8c22a6888ddf0a50b9b1a35e3885
https://doi.org/10.1215/s1152851703000413
https://doi.org/10.1215/s1152851703000413
Autor:
Darell D. Bigner, David A. Reardon, Karen Ziegler, James J. Vredenburgh, Cindy Bohlin, Christy Lentz, Holly Schweitzer, Sandra Tourt-Uhlig, Amy Walker, Susanne Jackson, Jeremy N. Rich, Mary Lou Affronti, Allan H. Friedman, Jennifer A. Quinn, Henry S. Friedman, Deborah H. Allen, John H. Sampson, Sridharan Gururangan, James M. Provenzale, James E. Herndon
Publikováno v:
Neuro-oncology. 6(2)
Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma. We now report the results of a phase 1 trial of irinotecan plus BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, for patients with recurrent o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b7af53f79a45b501803168416626474
https://pubmed.ncbi.nlm.nih.gov/15134629
https://pubmed.ncbi.nlm.nih.gov/15134629